OK HB1503

Defines "biological product," "biosimilar," and "interchangeable" using federal Public Health Service Act Section 351 definitions (42 U.S.C. Section 262).

Permits pharmacists to dispense a substitute biological product only if the FDA has determined it is biosimilar and interchangeable to the prescribed product and the prescribing practitioner has not expressed a preference against substitution in writing, verbally, or electronically.

Requires pharmacists to notify patients of the substitution and the retail price difference between the prescribed and substitute products, and inform patients they may refuse the substitution.

Requires pharmacists to notify the prescribing practitioner within 5 days of filling a substitute biological product and maintain written or electronic records of substitutions for at least 2 years.

Requires the State Board of Pharmacy to maintain a current list on its public website of biological products the FDA has determined are biosimilar and interchangeable.

Effective date: November 1, 2015.